Background-Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is associated with the risk of cardiovascular (CV) events in population-based studies. The prognostic value of Lp-PLA 2 in patients with acute coronary syndromes (ACS) has not been established. Methods and Results-Plasma levels of Lp-PLA 2 activity were measured at baseline (nϭ3648) and 30 days (nϭ3265) in patients randomized to atorvastatin 80 mg/d or pravastatin 40 mg/d after ACS in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. The primary end point was death, myocardial infarction, unstable angina, revascularization, or stroke (mean follow-up 24 months). At baseline after ACS, the risk of recurrent CV events was similar across all quintiles of Lp-PLA 2 activity (P trend ϭ0.88). Overall, mean levels of Lp-PLA 2 were lower at 30 days of follow-up than at baseline (35.7 versus 40.9 nmol · min Ϫ1 · mL Ϫ1 , PϽ0.001). In particular, treatment with atorvastatin 80 mg/d was associated with a 20% reduction in Lp-PLA 2 activity (PϽ0.001), whereas Lp-PLA 2 rose 3.6% with pravastatin 40 mg/d (PϽ0.001). Patients with 30-day Lp-PLA 2 activity in the highest quintile were at significantly increased risk of recurrent CV events compared with those in the lowest quintile (26.4% versus 17.6%, P trend ϭ0.002). After adjustment for cardiac risk factors, treatments, achieved low-density lipoprotein (LDL), and C-reactive protein, Lp-PLA 2 activity in the highest quintile remained independently associated with a higher risk of recurrent CV events (adjusted hazard ratio 1.33, 95% confidence interval [CI] 1.01 to 1.74).
I nflammation has been established as a key contributor to atherothrombosis. 1 As such, circulating levels of inflammatory biomarkers may provide important prognostic information beyond that obtained from traditional risk factors. 2 As new insights are gained about the pathophysiology of atherogenesis and plaque rupture, additional markers of inflammation may be identified that provide incremental value for assessing risk and guiding therapy.
Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is a 45-kD enzyme, also known as platelet-activating factor acetylhydrolase (PAF-AH), that is produced predominantly by macrophages and lymphocytes. 3, 4 In plasma, more than Clinical Perspective p 1752 two thirds of Lp-PLA 2 circulates bound to low-density lipoprotein (LDL), with much of the enzyme's activity concentrated in atherogenic small, dense LDL. 5 Early studies suggested the enzyme may have an antiinflammatory role, 6, 7 whereas growing evidence suggests that it acts in several pathways that contribute to atherogenesis. 8, 9 In addition, Lp-PLA 2 has been identified in atherosclerotic plaques 10 and is strongly expressed in macrophages found in lesions prone to rupture. 11 As such, there has been interest in the inhibition of the Lp-PLA 2 enzyme as a therapeutic target. 12 Although lipid-lowering therapies that include statins may lower circulating Lp-PLA 2 , [13] [14] [15] the clinical implications of this observation outside of LDL reduction remain unclear.
At least 4 large studies have shown an independent association between Lp-PLA 2 and the risk of future cardiovascular (CV) events in candidates for primary prevention. 16 -19 In addition, Lp-PLA 2 has been shown to be elevated in patients with coronary artery disease 20 -23 and to be associated with an increased risk of coronary events in patients with preexisting stable CV disease. 24, 25 In contrast, few data exist on the association of Lp-PLA 2 with prognosis in acute coronary syndromes (ACS).
We therefore investigated the prognostic utility of Lp-PLA 2 in a large cohort of patients presenting across the spectrum of ACS and assessed its incremental value to existing clinical risk factors. We also examined the association between Lp-PLA 2 , randomized types of statin therapies, and subsequent outcomes in PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction).
Methods

Study Population and Design
The design and results of PROVE IT-TIMI 22 have been reported previously. 26 In brief, PROVE IT-TIMI 22 was a multicenter, randomized, double-blind trial of 4162 patients to evaluate the effects of intensive (atorvastatin 80 mg daily) versus moderate (pravastatin 40 mg daily) statin therapy for the prevention of major adverse cardiac events after ACS. Randomization occurred in the first 10 days after the index event (median 7 days).
Patients were followed for 18 to 36 months after randomization (mean 24 months). The primary end point of the trial was a composite of death, myocardial infarction (MI), unstable angina that required hospitalization, revascularization (Ͼ30 days after randomization), or stroke. Elements of the primary end point were adjudicated by a clinical events committee. 26
Blood Sampling and Analysis
As part of the study protocol, a sample of venous blood was obtained in EDTA-treated tubes from the subjects at the time of enrollment and at 30 days' follow-up. The plasma component was frozen and shipped to a central laboratory where samples were stored at Ϫ70°C or colder. Lp-PLA 2 activity was measured with [ 3 H]-PAF as reaction substrate, using previously described methodology 18 at GlaxoSmith-Kline (Research Triangle Park, NC). Enzyme activity is expressed as nanomoles of PAF hydrolyzed per minute per mL of plasma samples (nmol · min Ϫ1 · mL Ϫ1 ). An aliquot of each sample and 2 aliquots of 3 plasma controls were each analyzed in 2 duplicate plates. The average intraplate and interplate coefficient of variations were both Ͻ7%, whereas the mean Lp-PLA 2 activity determined for each sample had an average coefficient of variation of 9.4% within the normal dynamic range of the assay.
After determination of Lp-PLA 2 activity, samples were frozen and subsequently thawed for determination of Lp-PLA 2 mass. Lp-PLA 2 mass measurements were performed with the PLAC Test at dia-Dexus Inc (South San Francisco, Calif). This assay consists of a sandwich-type immunoassay that uses 2 anti-Lp-PLA 2 monoclonal antibodies standardized to recombinant Lp-PLA 2 as described previously. 20, 27 Available plasma samples from baseline and after 30 days' follow-up were also measured for high-sensitivity C-reactive protein (CRP) (Denka Seiken, Tokyo, Japan) at the TIMI Biomarker Core Laboratory (Boston, Mass). 28 All biomarker testing was performed by personnel who were blinded to treatment arms, outcomes, and results of other biomarker testing.
Statistical Analysis
Continuous variables were compared with the Student t test, and categorical variables were compared with the 2 test. Correlations between levels of Lp-PLA 2 activity, Lp-PLA 2 mass, lipids, and CRP were examined with the Spearman correlation coefficient.
To evaluate its association with clinical outcomes, Lp-PLA 2 was analyzed as a continuous variable and categorized into quintiles according to Lp-PLA 2 level at baseline and after 30 days of follow-up. For this analysis, we defined achieved LDL, CRP, and Lp-PLA 2 as the levels obtained 30 days after initiation of study drug. Patients with an event before 30 days of follow-up were excluded from the 30-day analyses. Event rates were estimated by the Kaplan-Meier method.
Cox proportional hazards models were constructed to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for clinical events associated with levels of Lp-PLA 2 . The variables that were tested for inclusion in the model were age, gender, tobacco use, index diagnosis, prior MI, diabetes mellitus, prior renal disease, prior statin use, treatment arm, LDL, high-density lipoprotein (HDL), and CRP. With a stepwise approach to modeling (Pϭ0.1 for entry, Pϭ0.05 for retention), the final model consisted of age, index diagnosis, prior MI, diabetes mellitus, prior renal disease, treatment arm, LDL, and CRP. Analyses at 30 days included achieved CRP and achieved LDL as covariates in the model. We tested for an interaction of Lp-PLA 2 with the randomized statin regimen by entering an interaction term in the model. Stratified analyses were also performed based on treatment arm, statin use before index event, and LDL concentration above or below the median. For all analyses, a probability value Ͻ0.05 was considered to be statistically significant. Statistical analyses were performed with Stata version 8.2 (StataCorp, College Station, Tex).
The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results
Baseline Demographics and Clinical Presentation
Measurements of Lp-PLA 2 activity were available for 3648 participants (87.7%) at baseline. After 30 days' follow-up, 3265 participants (78.4%) were alive and free from a recurrent event and had a serum sample for measurement of Lp-PLA 2 .
In the study population, the index event was evenly divided between ST-elevation MI, non-ST-elevation MI, and highrisk unstable angina. More than two thirds of patients underwent percutaneous coronary intervention for management of their ACS before randomization, and one quarter were taking a statin before their event. The characteristics of the study population and achieved Lp-PLA 2 are displayed in Table 1 . Mean levels of Lp-PLA 2 at 30 days were higher among patients who were younger, male, white, or current smokers or who had a prior history of MI or hyperlipidemia. Mean levels of Lp-PLA 2 activity were lower in patients with a history of hypertension and were lowest in patients with ST-elevation MI as their index diagnosis.
Baseline Lp-PLA 2 Activity and Clinical Outcomes
At baseline after ACS, no significant association was evident between Lp-PLA 2 and the risk of subsequent outcomes ( Table  2) . Event rates for the primary end point were similar across all quintiles of Lp-PLA 2 activity (P trend ϭ0.88). Mean Lp-PLA 2 activity was similar in patients both with and without recurrent CV events (41.2 versus 40.8 nmol · min Ϫ1 · mL Ϫ1 , Pϭ0.76), including the individual elements of the composite 
Lp-PLA 2 Activity and Statin Therapy
After 30 days' follow-up, overall mean Lp-PLA 2 activity had decreased by 12.7% compared with mean activity at baseline (35.7 versus 40.9 nmol · min Ϫ1 · mL Ϫ1 , PϽ0.001). Notably, mean Lp-PLA 2 activity declined by 20% after treatment with high-dose atorvastatin (PϽ0.001), whereas mean Lp-PLA 2 activity rose by 3.6% in patients taking pravastatin (PϽ0.001; PϽ0.001 for the difference between treatment arms; Figure  1 ). For patients who were statin naïve before the index event, mean Lp-PLA 2 activity declined by 24% after 30 days in atorvastatin-treated patients (PϽ0.001) and remained unchanged in patients treated with pravastatin (Pϭ0.55; PϽ0.001, for the difference between treatment arms). In a linear regression model, treatment with high-dose atorvastatin was associated with a larger reduction in Lp-PLA 2 activity independent of the change in LDL (PϽ0.001). Both mean Lp-PLA 2 activity and LDL concentration were reduced after 30 days compared with baseline, and the correlation between the achieved values of these variables was significant (rϭ0.50, PϽ0.001), such that 25% of the variance in achieved Lp-PLA 2 was explained by achieved plasma LDL. A very weak correlation was evident between achieved Lp-PLA 2 activity and achieved CRP (rϭ0.07, PϽ0.001). Achieved Lp-PLA 2 activity did not correlate with HDL (rϭϪ0.02, Pϭ0.21) and correlated modestly with achieved triglycerides (rϭ0.36, PϽ0.001).
Thirty-Day Lp-PLA 2 Activity and Clinical Outcomes
Patients with Lp-PLA 2 activity in the highest quintile at 30 days were at significantly increased risk of recurrent CV events compared with patients with Lp-PLA 2 activity in the lowest quintile (26.4% versus 17.7%, P trend ϭ0.002, Figure  2 ). Notably, there was directional consistency across the individual end points of death, MI, and need for revascularization (Table 3) . Moreover, after we controlled for relevant clinical predictors including achieved LDL and achieved CRP, patients with Lp-PLA 2 activity in the highest quintile remained at significantly increased risk of the primary end point (adjusted HR 1.33, 95% CI 1.01 to 1.74), death or MI (adjusted HR 1.70, 95% CI 1.08 to 2.68), and recurrent MI (adjusted HR 1.98, 95% CI 1.17 to 3.34; Table 3 ).
For the purpose of placing the prognostic performance of Lp-PLA 2 in the context of our prior evaluation of CRP, 28 Lp-PLA 2 was also evaluated separately along with LDL and each of the relevant clinical predictors and was associated with a 1.69-fold (95% CI 1.08 to 2.65) higher risk of death or MI in the highest quintile of Lp-PLA 2 . By comparison, patients with CRP in the highest quintile were at 1.90-fold (95% CI 1.33 to 2.72) higher risk of death or MI after adjusting for the same variables.
When the association between Lp-PLA 2 activity and clinical outcomes was analyzed by treatment arm, Lp-PLA 2 was a significant predictor of MI (P trend ϭ0.004), revascularization (Pϭ0.04), and the primary end point (Pϭ0.04) among patients assigned to treatment with pravastatin, thereby eliminating the possibility of confounding by statin allocation. In patients treated with high-dose atorvastatin, the association appeared attenuated, with no statistically significant relationships observed between Lp-PLA 2 and the risk of subsequent CV events (P trend ϭ0.23); however, formal testing did not yield definitive statistical evidence of an interaction between treatment groups ( Table 3 ).
Lp-PLA 2 Mass and Clinical Outcomes
To compare our findings with a commercially available assay, Lp-PLA 2 mass was also measured in all available samples with the PLAC test (diaDexus, South San Francisco, Calif) mass assay. Samples were available for measurement in 3625 participants (87.1%) at baseline and 3263 participants (78.4%) at 30-day follow-up.
Only a modest correlation was apparent between Lp-PLA 2 activity and Lp-PLA 2 mass both at baseline (rϭ0.35, PϽ0.001) and at 30-day follow-up (rϭ0.36, PϽ0.001; Figure  3 ). When measured at baseline after an ACS, we observed no independent association between Lp-PLA 2 mass and the risk of future CV events.
At 30-day follow-up, patients with Lp-PLA 2 mass in the highest quintile had a statistically higher incidence of CV events than those with Lp-PLA 2 mass in the lowest quintile (22.8% versus 20.3%, P trend ϭ0.03). However, this association was no longer significant after adjustment for achieved LDL and other clinical risk indicators (adjusted HR 0.98, 95% CI 0.76 to 1.25). These results were similar across each element of the composite end point and when stratified by LDL concentration either above or below the median.
Discussion
This large-scale study of Lp-PLA 2 in a well-characterized population of patients with ACS provides several findings of clinical importance with respect to this emerging biomarker. In particular, we found that Lp-PLA 2 is not useful for risk stratification when measured in the early days after presentation with unstable coronary disease. However, when measured during follow-up, Lp-PLA 2 activity provides prognostic information that is incremental to that obtained from traditional risk factors, including both LDL and CRP.
Use of Lp-PLA 2 for Risk Assessment
Although elevated levels of Lp-PLA 2 have been shown to be associated with CV outcomes in population-based studies, 16 -19 few data are available with regard to its prognostic utility in patients with ACS. When measured early after an event, we found no independent association between Lp-PLA 2 activity or mass and the risk of recurrent CV events, regardless of prior statin use, treatment arm, or baseline LDL concentration.
There are several possible explanations for our findings that should be considered. As LDL concentrations fall unpredictably early after onset of ACS, 29 Lp-PLA 2 may variably diminish in tandem, thereby dampening the apparent association of both LDL and Lp-PLA 2 with outcomes. To that end, Stephens and colleagues 30 observed a reduction in both LDL and Lp-PLA 2 activity during the first several days after ACS compared with the time of presentation. Another factor that could theoretically influence the prognostic utility of the marker is the widespread inflammation that accompanies ACS. 31, 32 Yet, it remains unclear whether Lp-PLA 2 is an acute-phase reactant, because enzyme levels have been shown to rise or fall in response to inflammatory stimuli in both human and animal models. [33] [34] [35] Another consideration is randomized statin use in the PROVE IT-TIMI 22 cohort. Although lipid-lowering therapy can variably influence levels of Lp-PLA 2 and its predominant carrier LDL, it is unlikely that our baseline findings can be explained by treatment effect alone, because they were confirmed in an additional 2351 patients with ACS who were on much lower rates of lipid-lowering therapy (see online-only Data Supplement at http://circ.ahajournals.org/cgi/content/full/ CIRCULATIONAHA.105.612630/DC1).
Importantly, we found that elevated levels of Lp-PLA 2 activity are independently associated with an increased risk of recurrent CV events, but only when measured at a time when patients were distanced from the acute inflammatory response to the index event. This observation resolves the potential discordance between the lack of prognostic value of the baseline measurement in the present study and prior studies that have shown an association between Lp-PLA 2 , prevalent coronary artery disease, and future vascular events. 20 -25 Comparable to prior studies, the relative hazard for subsequent CV events for patients with the highest levels of Lp-PLA 2 activity was Ϸ1.3 after we accounted for traditional risk factors. Notably, directional consistency was observed across most of the individual end points, including death, recurrent MI, and the need for coronary revascularization. Moreover, determination of Lp-PLA 2 activity provided incremental prognostic information to that provided by traditional risk factors, including LDL and CRP.
Influence of Intensive Statin Therapy
The PROVE IT-TIMI 22 trial provided the opportunity to explore the effects of moderate and intensive statin therapies on levels of Lp-PLA 2 in a randomized design. Intensive statin therapy with atorvastatin 80 mg/d was associated with a mean 20% reduction in Lp-PLA 2 activity and a 23% reduction in Lp-PLA 2 mass. In contrast, patients treated with pravastatin 40 mg/d observed a much smaller change in Lp-PLA 2 activity (3.6%) or mass (Ϫ4.5%). Importantly, the larger reduction in Lp-PLA 2 activity observed with atorvastatin 80 mg/d was only partially explained by the change in LDL. Although a definitive interaction with treatment group was not observed, the present findings are hypothesis generating, raising the possibility that intensive statin therapy may help to partially attenuate the risk associated with higher levels of Lp-PLA 2 .
Moreover, pharmacological interventions aimed at inhibiting the Lp-PLA 2 enzyme may provide incremental benefit to intensive lipid-lowering therapy and are now under investigation. 12
Lp-PLA 2 Activity Versus Mass
Our finding of a modest correlation between Lp-PLA 2 as measured by the mass and activity assays (rϭ0.36) contrasts with a much stronger correlation (rϭ0.86) that was previously reported in a smaller study of 148 males, which used an earlier version of the mass assay. 20 To date, there have been limited data comparing assay performance on a large scale across different patient populations. The present findings raise important questions about factors that may influence Lp-PLA 2 enzyme activity independently of its quantified mass, including various therapies and disease states. Lipoproteins have been shown to alter the catalytic behavior of Lp-PLA 2 in human plasma, 36 with enhanced enzyme activity seen in association with LDL as opposed to enzyme bound to HDL. One could speculate that changes in lipoprotein distribution and particle size after ACS could lead to a differential effect on enzyme mass and activity. Moreover, Lp-PLA 2 enzyme activity is determined by the rate of PAF hydrolysis in vitro, yet the ability to hydrolyze PAF is not limited to Lp-PLA 2 . Various other plasma enzymes, including lecithin cholesterol acyltransferase (LCAT), are capable of PAF hydrolysis and may upregulate this function during periods of oxidative stress. [37] [38] [39] Many of the larger primary prevention studies explored the association between Lp-PLA 2 and CV events using measurements of Lp-PLA 2 mass. 16, 17, 19, 40 The WOSCOPS (West Of Scotland COronary Prevention Study) and MONICA (MONItoring trends and determinants in CArdiovascular disease) studies both found an independent association between Lp-PLA 2 and the risk of coronary heart disease, 16, 19 whereas in the ARIC (Atherosclerosis Risk In Communities) study, an independent association was observed in patients with an LDL concentration Ͻ130 mg/dL. 17 However, in our study of patients with recent ACS, the association between achieved Lp-PLA 2 mass and CV outcomes was largely attenuated after controlling for baseline variables. Similarly, no independent association was observed between Lp-PLA 2 mass and future coronary events in the Women's Health Study population after other risk indicators were taken into consideration. 40 As such, possible differences in assay performance in various clinical settings are of interest and should be addressed in future studies.
Study Limitations
Limitations of the present study include the randomization of patients to statin therapies soon after ACS, which differentially influenced Lp-PLA 2 , LDL, and outcomes. Although we evaluated the prognostic utility of Lp-PLA 2 by treatment arm and LDL concentration, the presence of statin use may have partially attenuated the relationship between Lp-PLA 2 and subsequent events. However, the utility of Lp-PLA 2 testing in the setting of statin use remains particularly relevant because intensive statin therapy is frequently used in post-ACS management. 41 In addition, although 2 distinct time points were available for analysis, it is possible that stronger associations would be observed at different lengths of time after ACS. Owing to the absence of a placebo arm or plasma samples from the time of initial presentation, we are unable to ascertain whether Lp-PLA 2 levels were acutely elevated at the time of ACS and subsequently returned to baseline by 30 days.
Conclusions
In conclusion, in the present study, Lp-PLA 2 was not associated with an increased risk of recurrent CV events when measured early after ACS. As such, Lp-PLA 2 cannot be advocated for risk stratification at that time. Rather, the present data suggest that Lp-PLA 2 activity can offer additional prognostic information when assessed at a time significantly distanced from the acute coronary event. Additional understanding of available assay types is warranted to better understand the incremental utility of this biomarker. Moreover, intensive statin therapy is associated with significant lowering of Lp-PLA 2 independent of LDL. Future investigation will help to determine whether inhibition of the Lp-PLA 2 enzyme will prove to be a valuable therapeutic target.
